Literature DB >> 12890882

Macroprolactinemia: a new cause of hyperprolactinemia.

Naoki Hattori1.   

Abstract

Hyperprolactinemia is not only seen in pregnancy but also in several pathological conditions such as prolactin (PRL) secreting pituitary adenoma (prolactinoma), intracranial tumors compressing the pituitary stalk or hypothalamus, and PRL stimulative drugs. However, some patients with hyperprolactinemia are diagnosed as having idiopathic hyperprolactinemia because the causes are unknown. They are subjected to repeated radiological examinations to find a microadenoma, to a long-term treatment with bromocriptine, and even to a surgical intervention. There is accumulating evidence that macroprolactinemia, in which most circulating PRL forms large protein complexes (more than 150 kDa), is a major cause of idiopathic hyperprolactinemia. The patients with macroprolactinemia are clinically characterized by the lack of hyperprolactinemia-related symptoms such as amenorrhea and galactorrhea. We found that anti-PRL autoantibody is a leading cause of macroprolactinemia that might be heterogeneous in nature. Most patients with anti-PRL autoantibodies were symptom-free and pregnancy was possible despite a marked hyperprolactinemia. Identification of macroprolactinemia is clinically important to prevent unnecessary examinations and treatments in patients with idiopathic hyperprolactinemia.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12890882     DOI: 10.1254/jphs.92.171

Source DB:  PubMed          Journal:  J Pharmacol Sci        ISSN: 1347-8613            Impact factor:   3.337


  8 in total

1.  Prevalence of pituitary adenomas in macroprolactinemic patients may be higher than it is presumed.

Authors:  Gonca Tamer; Ayşegül Telci; Meral Mert; Ayse Kubat Uzum; Ferihan Aral; Refik Tanakol; Sema Yarman; Harika Boztepe; Nese Colak; Faruk Alagöl
Journal:  Endocrine       Date:  2011-09-30       Impact factor: 3.633

2.  Urine oligosaccharide pattern in patients with hyperprolactinaemia.

Authors:  Bertil Ekman; Jeanette Wahlberg; Eva Landberg
Journal:  Glycoconj J       Date:  2015-08-15       Impact factor: 2.916

Review 3.  Biochemical diagnosis in prolactinomas: some caveats.

Authors:  Stephan Petersenn
Journal:  Pituitary       Date:  2020-02       Impact factor: 4.107

4.  Identification of IgG-immunocomplex macroprolactin with an immunometric "sandwich" system: technical and clinical considerations.

Authors:  P Amadori; C Dilberis; A Marcolla; M Pinamonti; P Menapace; A Valentini
Journal:  J Endocrinol Invest       Date:  2004-12       Impact factor: 4.256

5.  Bromocriptine enhances the uptake of (99m)Tc-MIBI in patients with hepatocellular carcinoma.

Authors:  Xiangting Chai; Qiaoyu Liu; Wenyu Shao; Feng Zhang; Xuehao Wang; Hai Wang
Journal:  J Biomed Res       Date:  2012-04-12

6.  Hyperprolactinaemia - a problem in patients from the reproductive period to the menopause.

Authors:  Sylwia Pałubska; Aneta Adamiak-Godlewska; Izabela Winkler; Katarzyna Romanek-Piva; Tomasz Rechberger; Marek Gogacz
Journal:  Prz Menopauzalny       Date:  2017-04-26

7.  Evaluation of hyperprolactinemia risk factors in infertile women referred to Yazd Infertility Center: A cross-sectional study.

Authors:  Elahe Dehghan; Nasim Namiranian; Akram Ghadiri-Anari; Seid Kazem Razavi Ratki; Reyhaneh Azizi
Journal:  Int J Reprod Biomed       Date:  2022-01-12

Review 8.  Macroprolactinemia: new insights in hyperprolactinemia.

Authors:  Miro Kasum; Slavko Oreskovic; Ivana Zec; Davor Jezek; Vlatka Tomic; Vesna Gall; Goran Adzic
Journal:  Biochem Med (Zagreb)       Date:  2012       Impact factor: 2.313

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.